◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Zydus Lifesciences Limited (ZYDUSLIFE) Revenue 2022–2026

Name: Zydus Lifesciences Limited (ZYDUSLIFE) revenue history 2022-2026
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-09-20

Zydus Lifesciences Limited annual revenue for fiscal 2026 was ₹267.2 billion, an increase of 18.4% from ₹225.7 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.

ZYDUSLIFE Annual Revenue

Revenue (annual)	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹267.2B	₹225.7B	₹190.2B	₹168.8B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

ZYDUSLIFE Quarterly Revenue

Revenue (quarterly)	2026-06-30	2026-03-31	2025-12-31	2025-06-30	2025-03-31	2024-12-31
Total Revenue	₹78.0B	₹74.3B	₹67.8B	₹64.7B	₹62.9B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Revenue at Comparable Companies

DIVISLAB Revenue — Divi's Laboratories Limited
TORNTPHARM Revenue — Torrent Pharmaceuticals Limited
4523 Revenue — Eisai Co., Ltd.
4151 Revenue — Kyowa Kirin Co., Ltd.
CIPLA Revenue — Cipla Limited
LAURUSLABS Revenue — Laurus Labs Limited

More ZYDUSLIFE metrics: Gross Profit · Operating Income · Net Income · EPS · Free Cash Flow

All ZYDUSLIFE financial statements → Interactive ZYDUSLIFE charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.